PHASE 3 STUDY OF ENASIDENIB (ENA) VERSUS CONVENTIONAL CARE REGIMENS (CCR) IN OLDER PATIENTS WITH LATE-STAGE MUTANT-IDH2 (MIDH2) RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA (R/R AML)

Papayannidis C., DiNardo C., Montesinos P., Schuh A., Vyas P., Wei A., Ommen H., Semochkin S., Kim H., Larson R., Koprivnikar J., Frankfurt O., Thol F., Chromik J., Byrne J., Pigneux A., Thomas X., Salamero O., Vidriales M., Doronin V., Dohner H., Fathi A., Laille E., Yu X., Hasan M., Martin-Regueira P., de Botton S.

Type

Conference paper

Publication Date

2021-01-01T00:00:00+00:00

Volume

106

Pages

1 - 1

Total pages

0

Permalink Close